Movaxin and Pregnancy
Pregnant women are advised to avoid taking Movaxin, especially late in their pregnancy, unless their doctor has determined the potential benefits outweigh the potential risks to the fetus.
Tell your doctor if you are pregnant or plan to become pregnant while taking Movaxin, since it may impair your fertility and/or harm an unborn child.
It's unknown whether the medication will pass into breast milk.
Nonetheless, the drug should be avoided while breastfeeding, so tell your doctor if you are breastfeeding or plan to do so.
Never give Movaxin to a child under two years of age without first speaking to your doctor.
NSAIDs, including Movaxin tablets, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including Movaxin tablets, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
Rheumato > Movaxin tablets are indicated for relief of the signs and symptoms of rheumato >Clinical Studies (14.1) ].
Taking cyclosporine with Movaxin can increase the levels of cyclosporine in your body, causing kidney problems. If you take these drugs together, your doctor should monitor your kidney function.
Renal Toxicity and Hyperkalemia
Long-term administration of NSAIDs, including Movaxin, has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.
The renal effects of Movaxin may hasten the progression of renal dysfunction in patients with preexisting renal disease. Because some Movaxin metabolites are excreted by the k >see Drug Interactions (7) ].
No information is available from controlled clinical studies regarding the use of Movaxin in patients with advanced renal disease. Avo >see Clinical Pharmacology (12.3) ].
Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
Q: Is there a shelf life for Movaxin?
A: Shelf life is always a function of how the medication has been stored and how often the medication
Which drugs or supplements interact with Movaxin?
Movaxin may increase the blood levels of lithium (Eskalith, Lithobid) by reducing the excretion of lithium by the kidneys. Increased levels of lithium may lead to lithium toxicity.
Movaxin may reduce the blood pressure-lowering effects of drugs given to reduce blood pressure. This may occur because prostaglandins play a role in the regulation of blood pressure.
When Movaxin is used in combination with methotrexate (Rheumatrex, Trexall) or aminoglycosides (for example, gentamicin) the blood levels of the methotrexate or aminoglycoside may increase, presumably because their elimination from the body is reduced. This may lead to more methotrexate or aminoglycoside-related side effects.
Movaxin increases the negative effect of cyclosporine on kidney function and reduces the effect of furosemide (Lasix) and thiazide diuretics because of prostaglandin inhibition.
Individuals taking oral blood thinners, for example, warfarin (Coumadin), should avoid Movaxin because Movaxin also thins the blood, and excessive blood thinning may lead to bleeding.
Movaxin should be avoided by patients with a history of asthma attacks, hives, or other allergic reactions to aspirin or other NSAIDs. If aspirin is taken with Movaxin there may be an increased risk for developing a gastrointestinal ulcer.
Persons who have more than three alcoholic beverages per day may be at increased risk of developing stomach ulcers when taking Movaxin or other NSAIDs.
Cholestyramine (Questran), colestipol (Colestid), and colesevelam (Welchol) may decrease the effectiveness of Movaxin by preventing its absorption from the intestine.
Movaxin oral suspension contains sorbitol. Combining sodium polystyrene sulfonate (Kayexalate) with sorbitol may cause fatal intestinal necrosis. Therefore, Movaxin oral solution should not be combined with Kayexalate.
Cardiovascular Thrombotic Events
Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.
To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
There is no consistent ev >see Warnings and Precautions (5.2) ].
Status Post Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled clinical trials of a COX-2 selective NSA >see Contraindications (4) ].
Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next
four years of follow-up.
Avoid the use of Movaxin in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If Movaxin is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.
How should this medicine be used?
Movaxin comes as a tablet and suspension (liquid) to take by mouth. It is usually taken once a day with or without food. Take Movaxin at the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take Movaxin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Shake the suspension well before each use to mix the medication evenly.